Atara Biotherapeutics (ATRA) Non-Current Deffered Revenue (2020 - 2024)
Atara Biotherapeutics (ATRA) posted Non-Current Deffered Revenue of $470000.0 for Q3 2024, down 17.11% on a QoQ basis from $567000.0 in Q2 2024, and down 99.36% year-over-year from $73.9 million in Q4 2023.
Atara Biotherapeutics (ATRA) Non-Current Deffered Revenue (2020 - 2024) Analysis & Trends
Atara Biotherapeutics' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $470000.0 for Q3 2024.
- Quarterly Non-Current Deffered Revenue fell 99.36% year-over-year to $470000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $470000.0 (down 99.36% YoY) and the FY2023 annual result came in at $37.6 million, down 51.22% from the prior year.
- Non-Current Deffered Revenue was $470000.0 for Q3 2024 at Atara Biotherapeutics, down from $567000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $78.0 million in Q1 2023 and bottomed at $470000.0 in Q3 2024.
- A 5-year average of $39.9 million and a median of $39.9 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue surged 100.42% — and 2024, when it plunged 99.36%.
- Atara Biotherapeutics' Non-Current Deffered Revenue stood at $27.8 million in 2020, then jumped by 100.42% to $55.7 million in 2021, then surged by 38.22% to $77.0 million in 2022, then tumbled by 51.22% to $37.6 million in 2023, then sank by 98.75% to $470000.0 in 2024.
- Business Quant data shows ATRA's Non-Current Deffered Revenue at $470000.0 in Q3 2024, $567000.0 in Q2 2024, and $719000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 470,000.00 |
| Jun 30, 2024 | 567,000.00 |
| Mar 31, 2024 | 719,000.00 |
| Dec 31, 2023 | 37.56 Mn |
| Sep 30, 2023 | 73.93 Mn |
| Jun 30, 2023 | 75.57 Mn |
| Mar 31, 2023 | 78.04 Mn |
| Dec 31, 2022 | 77.00 Mn |
| Sep 30, 2022 | 42.34 Mn |
| Jun 30, 2022 | 43.33 Mn |
| Mar 31, 2022 | 45.00 Mn |
| Dec 31, 2021 | 55.71 Mn |
| Sep 30, 2021 | 26.84 Mn |
| Jun 30, 2021 | 22.47 Mn |
| Mar 31, 2021 | 31.81 Mn |
| Dec 31, 2020 | 27.80 Mn |